Adrenomed AG: Adrenomed is a German biopharmaceutical company specialized in preserving vascular integrity in life-threatening conditions by precision medicine. Adrecizumab, clinical stage, first-in-class monoclonal antibody, targets the vasoprotective peptide Adrenomedullin, to treat conditions associated with increased vascular leakage, endothelial barrier dysfunction and shock. Successfully concluded clinical AdrenOSS-2 trial, a biomarker-guided, double-blind, placebo-controlled, randomized, multicenter proof-of-concept Phase 2 trial, in 301 septic shock patients. Single infusion of Adrecizumab resulted in a significant and fast improvement of mean fluid balance, a surrogate endpoint for vascular leakage. Within 24 hours, Adrecizumab led to a significant and sustained improvement of systemic organ function (SOFA score). Subsequently, the relative mortality was significantly reduced by more than 50% after day 28 which persisted over 90 days. Excellent safety and tolerability demonstrated in P2 in addition to two Phase I trials. TAM ~ 350K septic shock patients in 7MM. Business is Effectively Protected by Strong IP Position.
Phase l or ll
Cardiovascular, Infectious Disease
Berlin, Berlin 16761
Berlin, Berlin 16761
Company Participants at European Biotech Investor Days 2021
Frauke Hein, PhD
Adrenomed AG, Chief Business Officer
Dr. Frauke Hein, co-founder and long-standing member of the Adrenomed management team (since 2011) and serves as Chief Business Officer (CBO). Previously, Dr. Hein held the position as Director R&D at B·R·A·H·M·S AG (2007-2009) and Thermo Fisher (2009-2011), where she was responsible for strategic planning, R&D alliance and portfolio management. She is former Director Life Sciences ZAB (2001-2007), responsible for start-up financing and R&D grant evaluation in Berlin-Brandenburg.
Adrenomed AG, CFO
Wolfgang Baiker, PhD
Adrenomed AG, CEO
Dr. Wolfgang Baiker, Chief Executive Officer (CEO) of Adrenomed, has over 30 years of experience in the biopharma industry. Before joining Adrenomed, Dr. Baiker served as President and CEO of Boehringer Ingelheim USA. Prior to that, he held various roles at Boehringer Ingelheim, including Head of Global Development, Head of Global Manufacturing and Global Quality, as well as Head of the Biopharmaceutical Business Unit. In addition, Dr. Baiker acts as a Venture Partner of Wellington Partners, chairs the Board of Trustees of the Max-Planck-Institute for Polymer Research and sits on multiple Boards of Biopharmaceutical start-up companies.